Campbell & Co Investment Adviser’s Definium Therapeutics DFTX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$468K	Buy	+24,755	New	+$420K	0.03%	773

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Campbell & Co Investment Adviser's DFTX Position: Q1 2026 in Review

Campbell & Co Investment Adviser opened a new position in Definium Therapeutics (DFTX) in Q1 2026: 24,755 shares worth $468K. The stake represents 0.03% of the portfolio and ranks #773 among its holdings.

247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

Campbell & Co Investment Adviser held 24,755 shares of Definium Therapeutics worth $468K as of Q1 2026.
Definium Therapeutics was a new Campbell & Co Investment Adviser position in Q1 2026.
Definium Therapeutics made up 0.03% of Campbell & Co Investment Adviser's portfolio in Q1 2026, its #773 holding.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.